Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease

American Journal of Hematology

Volumn 61, Issue 4, 1999, Pages 238-242

  Saito, Yasuhiro ^a   Wada, Hideo ^a   Yamamuro, Miho ^a   Inoue, Akiko ^a   Shimura, Minori ^a   Hiyoyama, Kazuyo ^a   Gabazza, Esteban C ^a   Isaka, Naoki ^a   Shiku, Hiroshi ^a   Takeya, Hiroyuki ^a   Suzuki, Koji ^a   Kumeda, Kousuke ^b   Kato, Hisao ^c   Nakano, Takeshi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Chronic coronary artery disease; Protein C; PTCA; TF; TFPI

Indexed keywords

ACTIVATED PROTEIN C; ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; D DIMER; FIBRIN MONOMER; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEIN C; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTERY DIAMETER; ARTICLE; BLOOD CLOTTING; CHRONIC DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIPLASMIN; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; CHRONIC DISEASE; CORONARY DISEASE; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PROTEIN C; PYRIMIDINE DIMERS; SERINE PROTEINASE INHIBITORS; THROMBOPLASTIN;

EID: 0032867771     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199908)61:4<238::AID-AJH3>3.0.CO;2-8     Document Type: Article

References (28)

1. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilation of coronary artery stenosis: Percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-71.
2. McGarry Jr TF, Gottlieb RS, Morganroth J, et al. The relationship of anticoagulation level and complications after percutaneous transluminal coronary angioplasty. Am Heart J 1986;123:1445-1451.
3. Meade TW. Hypercoagulability and ischemic heart disease. Blood Rev 1987;1:2-8.
4. Meade TW, Brozovic M, Chakrabarti RR, et al. Haemostatic function and ischemic heart disease; principal results of the Northwick Park heart study. Lancet 1986;2:533-537.
5. Davies MJ, Woolf N. Atherosclerosis: What is it and why does it occur? Br Heart J 1993;69(Suppl):S3-S11.
6. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86:2839-2843.
7. Sandest PM, Sirnes PA Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol 1989;72:391-396.
8. Moor E, Hamsten A, Karpe F, Bavenholm P, Blomback M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infection at a young age. Thromb Haemost 1994;71:707-712.
9. Schneider CL. The active principle of placental toxin: thromboplastin; its inactibator in blood: antithromboplastin. Am J Physiol 1947;149: 123-129.
10. Thomas L. Studies on the intravascular thromboplastin effect of tissue suspensions in mice. II. A factor in normal rabbit serum which inhibits the thromboplastin effect of the sedimentable tissue component. Bull Johns Hopkins Hosp 1947;81:26-42.
11. Broze G, Girard TJ, Novotny, WF. The lipoprotein-associated coagulation inhibitor. In Coller BS, ed. Progress in haemostasis and thrombosis, Philadelphia, PA: WB Saunders, 1990. p. 243-268.
12. Rapaport SI. The extrinsic pathway inhibitor, a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991;66:6-15.
13. Novotny WF, Brown SG, Mieltich JP, Rader DJ, Broze GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78:387-393.
14. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in postheparin plasma and in plasma from cancer patients. Blood Coagulation Fibrinolysis 1991;2:713-721.
15. Brandzaeg P, Sandset PM, Joo GB, Obstebo R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989;55:459-470.
16. Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagaya S, Minami N, Nakano T, Shiku H. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thrombo Haemost 1995;73:10-14.
17. Minamikawa K, Wada H, Wakita Y, Ohiwa M, Deguchi K, Shirakawa S, Hiraoka N, Huzioka H, Nakano T, Nishioka J, Hayashi T, Suzuki K. Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism. Thromb Haemost 1994;71:192-194.
18. Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H. An antitissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third kunitz domain (K3) of free-form TFPI but tot lipoprotein-associated forms in plasma. J Biochem 1995;118:178-182.
19. Kokawa T, Enjyoji K, Kamikubo Y, Haradashiba M, Koh H, Tsushima M, Yamamoto A, Kato H. Measurement of free form of tissue factor pathway inhibitor (TFPI) antigen in hyperlipidemia; Relationship between free form and endothelial cell-associated form of TFPI. Arterioscler Thromb Vase Biol (in press).
20. Kamei S, Kamikubo Y, Hamuro T, Fujimoto H, Ishihara M, Yonemura H, Miyamoto S, Funatsu A, Enjyoji K, Abumiya T, Miyata T, Kato H. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): Comparison with human TFPI. J. Biochem 1994;115, 708-714.
21. Tanigawa M, Wada H, Minamikawa K, Wakita Y, Nagaya S, Mori T, Tamaki S, Nishikawa H, Katuta Y, Nakano T, Hayashi T, Suzuki K, Shiku H. Decreased protein C inhibitor after percutaneous transluminal coronary aggioplasty in patients with acute myocardial infarction. Am J Hematol 1995;49:1-5.
22. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H, Tanigawa M, Nishikawa H, Yamada N, Isaka N, Nakano T, Kumeda K, Kato H. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction, Am J Hematol 1997;55:183-187.
23. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1996;52:165-170.
24. Brandtzaeg P, Sandset PM, Joo GB, Ovstebo R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin. Protein C, extrinsic pathway inhibitor and fibrinopeptide a in systemic meningococcal disease. Thromb Res 1989;55:459-470.
25. Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995;77:175-185.
26. Griffin JH, Evatt B, Zimmerman T, Kleiss A, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68: 1370-1373.
27. De Stefano V, Finazzi G, Mannuci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996;87: 3531-3544.
28. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. New Engl J Med 1995;313:1557-1563.